SEC Filing Summary
Filing and period: Form 10-K for Brooks Automation, Inc. for the fiscal year ended September 30, 2011, filed November 28, 2011. The request metadata identifies Azenta, Inc. and “2011 Q4,” but the supplied filing is for Brooks Automation, the predecessor company, and reports annual results with fourth-quarter information.
Business Context and Reporting Period
Brooks provided automation, vacuum, instrumentation, and global service solutions primarily to semiconductor manufacturing, with expanding exposure to life sciences, industrial capital equipment, and adjacent markets. Fiscal 2011 included the acquisitions of RTS Life Sciences and Nexus Biosystems and the June 2011 divestiture of the contract manufacturing business to affiliates of Celestica.
The company reported four segments: Brooks Product Solutions, Brooks Life Science Systems, Brooks Global Services, and Contract Manufacturing. The divested contract manufacturing operations remained in continuing operations because Brooks retained significant commercial relationships with the buyer.
Financial Performance and Position
| Metric | Fiscal 2011 | Fiscal 2010 | Change |
|---|---|---|---|
| Revenue | $688.1 million | $593.0 million | +16% |
| Gross profit | $223.0 million | $166.3 million | +34% |
| Gross margin | 32.4% | 28.0% | +4.4 percentage points |
| Operating income | $79.6 million | $47.0 million | +69% |
| Net income attributable to Brooks | $128.4 million | $59.0 million | +118% |
| Diluted EPS | $1.97 | $0.92 | +114% |
| Operating cash flow | $87.7 million | $27.9 million | +215% |
| Adjusted EBITDA | $111.2 million | $75.1 million | +48% |
Fiscal 2011 net income and EBITDA benefited materially from the $45.0 million pretax gain on the contract manufacturing divestiture. The company also recognized $2.0 million of income tax expense, compared with a $2.7 million tax benefit in fiscal 2010, while retaining a full valuation allowance against net deferred tax assets.
Revenue mix shifted toward non-semiconductor markets. Semiconductor capital equipment represented 65% of fiscal 2011 revenue versus 71% in fiscal 2010; industrial capital equipment increased to 11% from 8%, and life sciences contributed 2% after the acquisitions. Fourth-quarter semiconductor capital equipment revenue declined to 47% of revenue.
- Brooks Product Solutions revenue was $451.3 million, up 24%; segment operating income was $64.9 million.
- Brooks Global Services revenue was $88.8 million, up 19%; segment operating income was $13.3 million.
- Brooks Life Science Systems contributed $10.6 million of revenue and recorded a segment operating loss of $4.7 million, including acquisition-related effects.
- Contract Manufacturing revenue was $137.3 million, down 12% because the business was sold late in the fiscal year; segment operating income was $10.6 million.
Cash Flow, Liquidity, Debt, and Commitments
Cash, cash equivalents, and marketable securities totaled $205.8 million at September 30, 2011, including $58.8 million of cash and cash equivalents, $65.7 million of short-term securities, and $81.3 million of long-term securities. Working capital was $224.8 million, and total assets were $636.6 million.
The balance sheet does not identify material interest-bearing debt. Total liabilities were $118.0 million, compared with total equity of $518.6 million. Liquidity sources included $87.7 million of operating cash flow and $78.2 million of proceeds from the contract manufacturing sale. Major uses included $88.3 million for acquisitions, $66.6 million of net marketable-security purchases, $6.5 million of capital expenditures, and $5.2 million of dividends.
Contractual obligations totaled $80.9 million, consisting primarily of $24.6 million of operating leases, $7.9 million of pension funding obligations, and $48.4 million of purchase commitments and other obligations. The company also had $1.8 million of letters of credit, approximately $11.0 million of unrecognized tax benefits, and a $7.9 million unfunded pension obligation.
Material Changes Versus the Prior Comparable Period
- Revenue increased 16%, driven by higher semiconductor and non-semiconductor product demand and stronger services revenue.
- Gross margin expanded from 28.0% to 32.4%, primarily due to higher factory overhead absorption and the divestiture of the lower-margin contract manufacturing business.
- Research and development expense rose to $39.8 million from $31.2 million as Brooks invested in new products, particularly automated sample-management systems.
- SG&A increased to $102.5 million from $85.6 million, reflecting higher incentive compensation, headcount, acquisition costs, consulting, commissions, and intellectual-property expenses.
- Operating cash flow improved substantially, although inventory increased as semiconductor demand moderated late in the fourth quarter and service inventories were built.
- Goodwill increased to $84.7 million from $48.1 million, primarily from the RTS and Nexus acquisitions; no goodwill impairment was recorded in fiscal 2011.
- The company initiated a quarterly cash dividend of $0.08 per share and declared another $0.08 per share dividend payable in December 2011.
Guidance, Outlook, Risks, and Unusual Items
Management stated that recent semiconductor order rates had moderated and forecast first-quarter fiscal 2012 revenue to be 7% to 12% below fourth-quarter fiscal 2011 revenue. Management expected research and development spending growth to moderate from fourth-quarter fiscal 2011 levels and believed existing resources were adequate for planned working capital and capital expenditures for the next twelve months.
- The business remains exposed to cyclical semiconductor capital spending, volatile demand, pricing pressure, and rapid technological change.
- Customer concentration is significant: the top ten customers represented approximately 55% of fiscal 2011 revenue, and two customers represented 15% and 13%, respectively.
- International revenue represented 49% of fiscal 2011 revenue, exposing the company to foreign exchange, political, regulatory, trade, collection, and geopolitical risks.
- Brooks was integrating RTS and Nexus and assumed additional goodwill, intangible assets, pension obligations, and execution risk in entering the life sciences market.
- Inventory reserves were $24.7 million at year-end, with $2.2 million of fiscal 2011 charges for excess and obsolete inventory.
- The company recorded $1.0 million of restructuring charges and recognized $0.7 million of income from a litigation settlement. A further approximately $4 million of litigation-related income was expected if the related SEC settlement became final.
- Deferred tax assets remained subject to a full valuation allowance; management indicated a possible significant non-cash tax benefit if profitability continued in most jurisdictions.
- Management and the independent auditor concluded that disclosure controls and internal control over financial reporting were effective as of September 30, 2011.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is Brooks Automation, Inc., not Azenta, Inc.; verify whether a later corporate name or successor filing is intended.
- Separate recurring operating performance from the $45.0 million pretax divestiture gain and other litigation and acquisition-related items.
- Assess the sustainability of the 32.4% gross margin after the contract manufacturing divestiture and during the expected semiconductor slowdown.
- Review Nexus and RTS integration progress, life sciences segment losses, acquired intangible amortization, and potential goodwill impairment sensitivity.
- Monitor inventory levels, excess-and-obsolete reserves, purchase commitments, and the effect of demand moderation on working capital and cash conversion.
- Evaluate customer concentration, semiconductor-cycle exposure, international revenue, and the company’s ability to maintain quarterly dividends through a downturn.
- Verify the status and accounting impact of the remaining SEC and former-executive litigation settlement contingencies and the approximately $3.6 million potential reduction in unrecognized tax benefits.